CERVICAL SCREENING ANGELIKA KAUFMANN, ST4, UHCW, MEDICAL STUDENT INDUCTION, 2015.

Slides:



Advertisements
Similar presentations
HPV Testing and Genotyping
Advertisements

Cervical Screening and HPV testing
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Updates on Pap Smear Guidelines 2014
Speaker: Decca Mohammed, MD.  Statistics for cervical cancer and HPV  Association of HPV to cervical cancer, and other cancers  Prevention  Screening.
Sample Taker Training Cervical Cytology & Management of Abnormalities.
Cervical Cancer Cervical dysplasia Cervical cancer Causes Risk factors
Benign Conditions Of The Cervix Dr. Abdalla H. Elsadig MD.
HPV and cervical screening Test of cure
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Spotlight on Cervical Cancer Screening
HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA Roger J Rand.
Benign and premalignant disease of the cervix
Cervical Cancer: Prevention and Treatment
CERVICAL CANCER IN BOTSWANA By Monkgogi Khana Khomela and Wedu King.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
 Cervical cancer is a malignant tumour deriving from cells of the "cervix uteri", which is the lower part of uterus.  Begins in the lining of the cervix.
wrong to say cervical erosion -this condition appear at ( puberty ) ( pregnancy )
Case Presentations: Pre-Invasive Cervical Neoplasia
Screening for Disease Guan Peng Department of Epidemiology School of Public Health, CMU.
COLPOSCOPY Cervical Screening QARC Training School October 2012.
Cytopathology: Technique and Interpretation
S MEAR TAKERS U PDATE 18 TH S EPTEMBER 2014 HPV testing Immunisation Smears in pregnancy Describing the cervix. Screening lesbian and bi-sexual women Conditions.
Cervical Cancer Screening
Cervical screening Tim Wright Sept 07. Introduction What who when What who when Benefits (evidence) Benefits (evidence) Cost Cost Does it fit wilson’s.
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
Screening for Cervical Cancer by Visual Inspection Techniques Dr Aruna Batra VMMC & SJH.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Cervical Sample Taker Training 2015 THE NHS CERVICAL SCREENING PROGRAMME (NHSCSP)
What Is HPV? Human Papillomaviruses have an icosahedral shape, contain DNA, and are non-enveloped There are at least 100 different types of HPV Over 30.
Overview of NHS Cervical Screening Programme Cervical Screening QARC Training School October 2012.
Epidemiology of a Chronic Disease Exercise By Mary Murphy April 2008
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Cancer of Cervix Shashi. Sep-15 Introduction: Best example of cancer prevention. Best example of cancer prevention. Potentially curable if detected early.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
CIN and mimics Dr Michael Coutts Consultant Gynaecological Pathologist
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
1 Cervical Screening Programme, England, : Graphs.
Cervical Intraepithelial Neoplasm
Cancer of Cervix Shashi. Oct-15 Introduction: Best example of cancer prevention. Best example of cancer prevention. US Statistics: US Statistics: Leading.
Adult Medical-Surgical Nursing
Cases. Case 2 Case 3 Normal cervix - Spatula and brush.
Sheffield Gynaecological Cancer CentreSheffield Teaching Hospitals PRIMARY HPV SCREENING A view from colposcopy John Tidy Consultant Gynaecological Oncologist.
Premalignant lesions of the cervix. Applied anatomy.
NHS Cervical Screening Programme Introducing HPV triage and test of cure.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.
Dr. Ahmed jasim Ass.Prof.MBChB-DOG-FICMS COSULTANT OF GYN. & OBST. COSULTANT OF GYN. & OBST.
Cytopathology Feb
Cervical Cancer Screening NURS 541: Women’s Healthcare – Diagnosis and Management.
Chris Marshall Cardiff 4 th year Medical Student.
Understanding Test Results
WHO : when is screening effective?
Cervical Screening- Implementation and local audit
Public Health England leads the NHS Screening Programmes
NHS Cervical Screening Programme Introducing HPV Triage
INTRODUCTION: CERVICAL CANCER SCREENING
Cytology Codes & management Colposcopy- Management of cervical lesions
Dr N Shailaja Dr Pradeep
Public Health England leads the NHS Screening Programmes
SH-sheikhhasani Gyn-oncologist
The National Cervical Screening Programme
HUMAN PAPILLOMA VIRUS and CERVICAL CARCINOMA
No matter what the type of genetic screening, certain core principles should be followed before a program is introduced. Principles of Screening • The.
Cervical Screening Programme
Presentation transcript:

CERVICAL SCREENING ANGELIKA KAUFMANN, ST4, UHCW, MEDICAL STUDENT INDUCTION, 2015

OUTLINE  Cervical cancer  HPV  Screening in general  Cervical screening  The cervix  Smear results  Colopscopy

CERVICAL CANCER  new cases world wide/year  80% in the developing world  2800 cervical cancer cases in the UK/ year  Cervical screening saves approximately lives a year in England

RISK FACTORS FOR CERVICAL CANCER  HPV infection (99%)  Persistent HPV infection  High viral load  Smoking (increases risk x2)  Multiple sexual partners  Immunosuppression (HIV)  Low socio-economic status  prolonged use of oral contraceptive pill  number of pregnancies (higher number of pregnancies = higher risk).

HPV (HUMAN PAPILLOMA VIRUS)  Over 100 HPV subtypes  Low risk:6+ 11, causing anogenital warts + respiratory papillomatosis  High risk: (31, 33): oncogenic, causing:  Cervical cancer  Anal cancer  Oral cancer  Endemic, 95% of sexually active women will have HPV at some point in their life  Majority of women will gain immunity and fight off HPV

HPV VACCINATION  VLPs= “ virus like particles” (don’t contain DNA, non-infective)  UK: start of immunisation in yrs yrs old girls + catch up thereafter  Cervarix (bivalent) – HVP  Switched to Gardasil in 2012: quadrivalent  3 doses over 6 months (0/2/6 months)  Herd immunity  Long-term studies  ? Need for booster

WHO CRITERIA FOR SCREENING  The condition sought should be an important health problem for the individual and community  There should be an accepted treatment or useful intervention for patients with the disease  The natural history of the disease should be adequately understood  There should be a latent or early symptomatic stage  There should be a suitable and acceptable screening test or examination  Facilities for diagnosis and treatment should be available  There should be an agreed policy on whom to treat as patients  Treatment started at an early stage should be of more benefit than treatment started later  The cost should be economically balanced in relation to possible expenditure on medical care as a whole  Case finding should be a continuing process and not a once and for all project

CERVICAL SCREENING IN THE UK  Organised way  Failsafe mechanisms to ensure abnormal results are acted upon  Standards and Quality control of  The screener  The laboratories  Cyto- and Histopathologist  Colposcopists

LIQUID BASED CYTOLOGY LBC used in the UK since Oct % unsatisfactory smears

NHS CERVICAL SCREENING PROGRAMME (NHSCSP)  Liquid based cytology (LBC)  Since 2003 (England)  Age 25-50: every 3 years  Age 51-65: every 5 years  Scotland + Wales:  Smears before the age of 25 could lead to unnecessary increased cervical treatment with potential negative consequences for future child bearing  Sensitivity 70%  10% false negative smears

CERVICAL SCREENING PROGRAMME 2  Disabled women  Women of ethnic minorities: communication/ leaflets/ information  Lesbian/ bisexual women advised to be screened (“low risk, but not no risk”)  Post hysterectomy  Women with sub-total hysterectomy still require cervical screening  Indication of hysterectomy: ie FU required for persistent CIN (vault smears)

CERVIX  Ectocervix: multiple layers non-keratinizing stratified SQUAMOUS epithelium  Endocervix: single layer COLUMNAR epithelium  Transformation zone = area where columnar epithelium has undergone metaplasia to become squamous epithelium. Between the new and original squamo-columnar junction (Type 1/2/3).

TRANSFORMATION ZONE-COLPOSCOPIC VIEW External os Glandular epithelium/ectropion On ectocervix in Puberty Pregnancy Few weeks post natal (baby girl) New squamo-columnar junction Original squamo-columnar junction TRANSFORMATION ZONE

SMEAR TEST RESULTS DYSKARIOSIS is a cytological diagnosis:  increased nuclear:cytoplasmic ratio  mitotic figures  nuclear pleomorphism  nuclear hyperchromasia  HPV features  koilocytosis (vacuolated cells)  hyperkeratosis  multinucleation

SMEAR TEST RESULTS  Normal  Borderline change (with high risk HP)  In squamous or endocervical cells  Low grade dyskariosis  High grade dyskariosis (moderate)  High grade dyskariosis (Severe)  ?glandular neoplasia of endocervical type  ?Glandular neoplasia (non-cervical)  Invasive disease Refer to colposcopy

TESTING FOR HPV  Cytology and HPV, currently being implemented  If high risk HPV positive, refer to colposcopy.  HPV as test of cure  HPV as primary test as precursor of cytology(currently being evaluated)

COLPOSCOPY  Chaperone/ nurse  Communication!!  Ascitic acid (3%)  Iodine  Colposcope

COLPOSCOPY IMAGES Normal cervix CIN Punctations Mosacicism Normal cervix Iodine negative

CIN (CERVICAL INTRAEPTHELIAL NEOPLASIA) = histological diagnosis  CIN 1 – bottom 1/3 abnormal  CIN 2- bottom 2/3 abnormal  CIN 3- full thickness abnormality CIN2 CIN3 CIN 1CIN 2CIN 3 Regress57%43%32% Persist32%35%56% Progress11%22% Invasive carcinoma 1%5%>12%

TREATMENT OF CIN CIN1  low malignant potential  will usually resolve spontaneously  encourage woman to quit smoking  if persistent may be treated (excision/ablation) CIN 2/3  higher malignant potential  standard treatment is excisional biopsy  offer 'see-and-treat' treatment  Treatment: excisional (ie LLETZ: large loop excision of transformation zone)

COLPOSCOPY IN PREGNANCY  Defer routine screening (12 weeks postpartum).  Difficult examination, only to be done by experienced colposcopist.  Oedematous cervix  Increased vascularity  Ectropion (hyperoestrogenism)  Aim: to exclude invasive disease.  Biopsy only to exclude invasive lesions.  If known smear abnormalities, arrange postpartum follow-up (3–4 months post delivery).

CASE 26 year old woman, first smear, referred with high grade-dyskariosis  How would you explain the smear test result?  What would you like to do next?  How do you explain the examination/ treatment?